Navigation Links
Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
Date:5/2/2013

00 mL, 10 mg / mL; for intravenous use only), Cadence Pharmaceuticals' proprietary intravenous formulation of acetaminophen, is indicated for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics, and the reduction of fever. The FDA approval of OFIRMEV was based on data from clinical trials in approximately 1,020 adult and 355 pediatric patients. These trials included two studies evaluating the safety and effectiveness of OFIRMEV in the treatment of pain, and one study evaluating OFIRMEV in the treatment of fever. The effectiveness of OFIRMEV for the treatment of acute pain and fever has not been studied in pediatric patients less than 2 years of age.

Important Safety InformationDo not exceed the maximum recommended daily dose of acetaminophen. Administration of acetaminophen by any route in doses higher than recommended may result in hepatic injury, including the risk of severe hepatotoxicity and death. OFIRMEV is contraindicated in patients with severe hepatic impairment, severe active liver disease or with known hypersensitivity to acetaminophen or to any of the excipients in the formulation. Acetaminophen should be used with caution in patients with the following conditions: hepatic impairment or active hepatic disease, alcoholism, chronic malnutrition, severe hypovolemia, or severe renal impairment. OFIRMEV should be administered only as a 15-minute intravenous infusion. Discontinue OFIRMEV immediately if symptoms associated with allergy or hypersensitivity occur. Do not use in patients with acetaminophen allergy. The most common adverse reactions in patients treated with OFIRMEV were nausea, vomiting, headache, and insomnia in adult patients and nausea, vomiting, constipation, pruritus, agitation, and atelectasis in pediatric patients. The antipyretic effects of OFIRMEV may mask fever in patients treated for post-surgical pain.

For more information, please see the complete OFIRME
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Cadence Pharmaceuticals Reports Second Quarter 2012 Financial Results
2. Cadence Pharmaceuticals To Present At The Deutsche Bank Securities, Inc. 37th Annual Health Care Conference In Boston On May 8, 2012
3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2011 Financial Results on March 12, 2012
4. Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.
5. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
6. Aurigenes Collaboration Programs with Endo Pharmaceuticals Reach Important Milestones
7. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
8. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ
9. Global Nuclear Medicine / Radiopharmaceuticals Market worth $5.55 Billion by 2017
10. US Radiopharmaceuticals (USR) Awards Contract to Von Gahlen International for New Technetium-99m Generator Production Line Using Low Enriched Uranium Molybdenum-99
11. Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Wash. , July 31, 2014   BioLife ... leading developer, manufacturer and marketer of proprietary clinical grade ... media and precision thermal shipping products for ... second quarter 2014 financial results will be released on ... host a conference call and live webcast at 4:30 ...
(Date:7/31/2014)... July 31, 2014 Boston’s Adult Stem ... flush with innovative adult stem cell biotechnologies. Currently ... and has three additional patent applications currently under examination ... patented inventions address two of the most vexing problems ... Adult stem cells are difficult to identify; and ...
(Date:7/30/2014)... PARIS , July 30, 2014  Regeneron Pharmaceuticals, ... SNY) today announced that the Companies intend to use ... disease priority review voucher in connection with the Biologics ... voucher entitles the holder to designate a BLA for ... from the filing date instead of the standard 10-month ...
(Date:7/30/2014)... 30, 2014 A study presented at ... and efficacy of CSL Behring,s C1 Inhibitor (C1-INH) ... in highly sensitized patients. C1-INH is a human ... system. The study shows that post-transplant ... the levels of complement components 3 and 4, ...
Breaking Biology Technology:BioLife Solutions to Report Financial Results for Second Quarter 2014 and Provide Business Update on August 7, 2014 2The Adult Stem Cell Technology Center, LLC Launches A Marketing Campaign To License Adult Stem Cell Biotechnologies 2The Adult Stem Cell Technology Center, LLC Launches A Marketing Campaign To License Adult Stem Cell Biotechnologies 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 2Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 3
... Baltimore Convention Center - September 21-23, 2009 ... summit will attract more than 1,200 experts from more than 25 ... 100 speakers, including governors, federal officials, and top researchers and scientists ... human-interest stories. This is your chance to meet and talk ...
... Aug. 11 ValGenesis, Inc., a leading provider ... availability of Microsoft SharePoint Server integration with the ... productivity specifically for regulated Pharmaceuticals, Biotech and Medical ... access, retrieval and storage of corporate validation data ...
... , NEWTON, Mass., Aug. 11 Microfluidics International Corporation ... quarter ended June 30, 2009. , , ... quarter accomplishments: , , Achieved positive ... Delivered strong bookings of $6.6 million with ...
Cached Biology Technology:World Stem Cell Summit to Be Held in Baltimore 2ValGenesis, Inc. Announces Integration of ValGenesis Solution with Microsoft SharePoint Server 2Microfluidics International Corporation Announces Second Quarter 2009 Financial Results 2Microfluidics International Corporation Announces Second Quarter 2009 Financial Results 3Microfluidics International Corporation Announces Second Quarter 2009 Financial Results 4Microfluidics International Corporation Announces Second Quarter 2009 Financial Results 5Microfluidics International Corporation Announces Second Quarter 2009 Financial Results 6Microfluidics International Corporation Announces Second Quarter 2009 Financial Results 7Microfluidics International Corporation Announces Second Quarter 2009 Financial Results 8Microfluidics International Corporation Announces Second Quarter 2009 Financial Results 9
(Date:7/31/2014)... July 31, 2014 Biometrics industry ... innovative smart technologies; companies turn towards digital currency: NXT-ID, ... ), Amazon.com Inc. (NASDAQ: AMZN ), Facebook ... GOOG ) and Microsoft Corporation (NASDAQ: MSFT) ... on the growing m-commerce market, announces a video featuring ...
(Date:7/30/2014)... York University is paving the way for a ... and military troops exposed to poisonous chemicalsparticularly those ... article in the current issue of the journal ... organophosphates, which are compounds commonly used in pesticides ... by NYU School of Engineering Associate Professor of ...
(Date:7/30/2014)... Chemical Society (ACS) announced today that David L. Kaplan, ... Biomaterials Science & Engineering as editor-in-chief. With the ... new journal will feature high-quality research in the rapidly ... naturally derived materials that interact with living or biological ... reflects the tremendous growth in the field of biomaterials ...
Breaking Biology News(10 mins):Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 2Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 3Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 4Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 5Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 6Engineering a protein to prevent brain damage from toxic agents 2ACS Biomaterials Science & Engineering: Brand-new journal launches in 2015, names editor 2
... is threatening the time-honored transmission of plant knowledge from ... and nutrition. In a novel study published online this ... Sciences, researchers report that parents, and especially mothers, who ... have healthier children, independent of other factors such as ...
... National Museum of Natural History in Washington, D.C., have ... of what they regard as one of the weirdest ... that the organism was a fungus, the scientists report ... published by the Geological Society of America. Called Prototaxites ...
... long been known that UV light can damage DNA, reducing ... resulting in the development of skin cancers. However, not much ... altered upon exposure to UV light. Now a group of ... changes in the mechanical properties of DNA upon irradiation with ...
Cached Biology News:Mother knows best: Plant knowledge key to childhood health in remote Amazon 2Prehistoric mystery organism verified as giant fungus 2Prehistoric mystery organism verified as giant fungus 3Prehistoric mystery organism verified as giant fungus 4Stretching DNA to the limit 2